Key result
Incidental venous thromboembolism in cancer patients carries similar prognostic implications to symptomatic events, and current evidence supports the use of standard anticoagulation for its management.
Why the study?
Does standard anticoagulation improve outcomes in patients with cancer and incidental venous thromboembolism?
Does standard anticoagulation improve outcomes in patients with cancer and incidental venous thromboembolism?
Incidental VTE in cancer patients should generally be treated with standard anticoagulation, similar to the management of symptomatic events.
Answers are grounded in this paper and cite their sources.
Suggests incidental cancer-associated VTE may merit anticoagulation; leaves open need for randomized confirmation before practice change.
Venous thromboembolism (VTE) is a frequent clinical complication of cancer and its treatment. Although much of the epidemiologic data regarding this complication have been based on symptomatic events, the use of multidetector row CT scanner technology has led to increased identification of VTE on scans ordered primarily for staging or restaging of malignancy. These incidentally discovered VTEs are variously referred to in the literature as incidental, asymptomatic, unexpected, or unsuspected VTE. A recent guidance paper by the Hemostasis and Malignancy Subcommittee of the International Society on Thrombosis and Haemostasis provided recommendations regarding this terminology (now termed incidental) and reporting of incidental VTE for clinical trials. A growing number of retrospective and case-controlled reports have described the prevalence, prognostic implications, and treatment options for these incidentally discovered VTE events, and have reported similar clinical outcomes for patients with incidental and symptomatic VTE. Because most reported patients with incidental VTE have been treated in a manner similar to those with symptomatic events, the present recommendations, except in rare circumstances, support the use of standard anticoagulation in the management of incidental deep vein thrombosis and pulmonary embolism.
No takes yet. Share an insight, caveat, or question.
O’Connell et al. (2014) conducted a review in Incidental venous thromboembolism (VTE) in cancer patients. Standard anticoagulation was evaluated. Incidental venous thromboembolism in cancer patients carries similar prognostic implications to symptomatic events, and current evidence supports the use of standard anticoagulation for its management.
Synapse has enriched 10 related papers. Consider them for comparative context: